| Revenue growth | 6.9% YoY revenue growth driven by non-GPL segment and new launches. |
|---|---|
| Margins | Record 33.6% EBITDA margin due to favorable product mix and efficiency. |
| Demand visibility | Stable demand in regulated markets; watchful of geopolitical uncertainty. |
| Management confidence | High; emphasizing resilience and successful transition under Nirma's ownership. |
Growth
FY26 revenue grew 6.9% to ₹2,552cr, led by 13% non-GPL growth; EBITDA margins expanded 366bps to 33.6%.
Outlook
Planned FY27 capex of ₹540cr for Solapur and Taloja R&D; targeting 2,690 KL capacity by FY28.
Risks
Dahej plant fire caused ₹20cr loss; global supply chain disruptions and solvent cost inflation remain persistent threats.
Earnings Call filed with BSE, NSE: ALIVUS. Summary written with AI assistance from the document.
Alivus Life Sciences Ltd: key numbers
- Share price
- ₹1,365.60
- Market cap
- ₹16,766 Cr
- Revenue (annual)
- ₹2,552 Cr
- Net profit (annual)
- ₹564.5 Cr
- P/E (TTM)
- 27.8×Sector 50.4×
- Promoter holding
- 74.87%+0.00% QoQ
- FII holding
- 5.54%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Alivus Life Sciences Ltd
All →Alivus Life Sciences Merger & Restructuring Worth ₹0.9 Cr
Alivus Life Sciences incorporated a wholly owned pharma subsidiary in Brazil. The company subscribes up to R$500,000 (₹0.90 Cr) for 100% of the new entity.
- Value
- ₹0.90 Cr
Alivus Life Sciences Annual General Meeting
Alivus Life Sciences Limited successfully conducted its 15th Annual General Meeting on September 8, 2026. All resolutions proposed in the AGM notice were passed with requisite majority.
Alivus Life Sciences Earnings Call Transcript: Key Takeaways
Alivus reported strong Q1 FY27 results with 6.4% revenue growth, masking a massive 52.6% decline in its legacy GPL business through high-margin non-GPL growth and operational efficiencies.
- Call
- Guides 11% growth
Alivus Life Sciences Investor Presentation: Key Takeaways
Alivus Life Sciences delivered strong Q1FY27 performance with revenue at ₹6,404 Mn and EBITDA margins expanding to 36.6%. The company is pivoting towards Non-GPL segments and CDMO growth.
- Call
- Guides 11% growth
Alivus Life Sciences Q1 FY27 Results: Net Profit ₹160.1 Cr, Up 31.8% YoY
Alivus Life Sciences Ltd reported revenue from operations of ₹640.4 Cr (+6.4% YoY) and net profit of ₹160.1 Cr (+31.8% YoY) for Q1 FY27.
- Key figure
- Net profit ₹160.1 Cr · +31.8% YoY
Alivus Life Sciences Earnings Call: Key Takeaways
Alivus (ex-Glenmark Life Sciences) reported strong Q4FY26 results with record 33.6% EBITDA margins, driven by non-GPL growth (71% of business) and CDMO recovery.